1. JORGE ALLINA
50-05 43rd Avenue Apt 4B Woodside, NY 11377
718-440 2788 jallina@yahoo.com
PROFESSIONAL EXPERIENCE
May 2014 - CarePoint Health Research Institute
Current Bayonne Medical Center
29 East 29th Street at Avenue E, Bldg A-4th Floor
Bayonne, New Jersey 07002
Clinical Research Coordinator
2009 - Assistant Professor
2011 Department of Environmental Medicine
New York University
New York, New York
2009 - Adjunct Assistant Professor
2011 Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
2006 - Assistant Professor
2009 Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
2001- Postdoctoral Fellow
2006 Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
1996 - General Practice Coordinator
1999 Clinica Laura Alejandra
Bogota DC, Colombia
1996 - Family Practice
1998 Private Practice

2. Bogota DC, Colombia
1995 – Family Practice
1996 Confiar Salud
Bogota DC, Colombia
1992 – Emergency and Office Physician
1995 Sopo’s Hospital
Cundinamarca, Colombia
1992 – Director
1993 Rural Hospital
Vergara-Cundinamarca, Colombia
EDUCATION AND CREDENTIALS
COLLEGE
1992 – Doctor of Medicine and Surgery
1988 Pontificia Universidad Javeriana
Bogota, Colombia
CERTIFICATION
CITI Good Clinical Practice
CITI HIPS/1
NIH Protecting Human Subject Research Participants
IATA: For the Shipping of Infectious Substance Affecting Humans; Biological Substance
Certificate of Attendance: Continuing Medical Education Dept. of Breast Service Tumor Board
Novatris “Good Clinical Practice” E-Learning Training
Novo Nordisk: Diabetes Trial Overview – IV/WRS Site Staff Training C3 v2, Become EDC
Informed for CRCs, Safety Information Form in Inform for Site staff v2, Technical Complaint
Reporting, Meal Test & Continuous Glucose Monitoring, Event Adjudication and Informed
Consent Certification
Maestro Module 1- 9: OnLine Education Program
Datatrak: eCLINICAL Data Collection Course
Oracle InForm GTM 5.5 for Site Users (CRC

3. OmniComm-eLearning Course: TM v4.1 Study Coordinator
Medidata Abbvie Rave Site Coordinator Training
ORIGINAL RESEARCH MANUSCRIPTS
1. Cuevas AJ, Liberda E, Gillespie P, Allina J, Chen LC. Inhaled nanoparticles alters vascular
reactivity in C57BL/6 Mice. Inhalation Toxicology 2010.
2. Hui-Hui Tan, MI Fiel, Q Sun, J Guo, RE. Gordon, LC Chen, SL Friedman, JA. Odin, J
Allina. Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-
alcoholic fatty liver disease. J Immunotoxicology.2009, Dec;6(4):266-75.
3. Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H Jr, Odin JA. Atorvastatin does not
improve liver biochemistries or mayo risk score in primary biliary cirrhosis. Dig Dis Sci, 2008
Jul; 53(7);1988-93.
4. Allina J, Stanca CM, Garber J, Hu B, Sautes-Fridman C, Bach N, Odin JA. Anti-CdD16
autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J
Autoimmun 2008 Jun;30(4):238-45.
5. Allina J, B Hu, D Sullivan, Fiel MI, Thung SN, Bronk SF, Heubert RC, van der Water J,
LaRusso NF, Gershwin ME, Gores GJ, JA Odin. T cell targeting and phagocytosis of apoptotic
biliary epithelial in primary biliary cirrhosis. J Autoimmun. 2006 Dec;27(4):232-41.
6. Stanca CM, Fiel MI, Allina J, Caracta CF, Odin JA. Liver failure in an antimitochondrial
antibody-positive patient with sarcoidosis: primary biliary cirrhosis or hepatic sarcoidosis?
Semin Liver Dis. 2005 Aug; 25(3):364-70.
7. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA,
Germain D, Friedman SL. Cyclin dependent kinase inhibition by the KLF6 tumor suppressor
protein through interaction with cyclin D1. Cancer Research. 2004 Jun ;(64), 3885-3891.
8.Sasaki M, Allina J, Odin JA, Thung SN, Coppel R, Nakanuma Y, Gershwin ME. Autoimmune
cholangitis in the SJL/J mouse is antigen non-specific. Dev Immunol. 2002 Jun;9(2):103-11.
REVIEWS
1. Odin JA, Allina J. Etiology and pathogenesis of primary sclerosing cholangitis. FAlk
conference, Berlin 2005.
MENTEES
Hui Hui Tan M.D, Singapore University Visiting Fellow. Mount Sinai School of Medicine
2008. Now onstaff at Singapore Hospital.
Monique Delisser, Pre-Medical Student, Mount Sinai School of Medicine 2007-2008. Now a
medical student at OSU.
Vineet Singal, High school student. Mount Sinai School of Medicine 2007-2008. Now a College
Student. Berkeley University
Azita Cuevas, Master of Public Health student, NYU 2010, thesis advisor.
Gregory Bach, College Student at Michigan University, NYU 2010 summer intern.

4. GRANTS
2007-2010 American Liver Foundation Jerome B. Zeldis, MD Liver Scholar. “Effects of Air Particulate
Matter on Liver Cell Function.” The major goal of this award was to determine which hepatic cells are
directly affected by air particulate matter binding.
2005-2009 Hirschl Foundation Odin (PI) Analysis of Macrophage Function and Gene
Expression in Primary Biliary Cirrhosis” The major goal of this award is to identify the etiology
of impaired macrophage phagocytosis in PBC.
2006-2008 American Liver Foundation Odin (PI) “Does Vitamin D Enhance Macrophage
Phagocytosis in PBC?” The goal was to evaluate the effect of Vitamin D3 on macrophage function and
serum liver function tests in those with PBC.
2001-2006 NIH NIDKK K08 Odin(PI) “The Role of Apoptotic Cholangiocytes in PBC”
The objective of this study was to determine if apoptotic cholangiocytes are a source of
immunogenic peptides in PBC.
RESEARCH
CLINICAL RESEARCH
Main Clinical ResearchCoordinator: HealthPoint - Protocol #: 802-247-09-031 - A Phase 3
Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of
HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
Main Clinical ResearchCoordinator: DermaSciences - Protocol #: DSC127-2012-01 - A
Randomized, Double-Blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate
the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects with
Diabetes Mellitus
Main Clinical ResearchCoordinator: Novo Nordisk - Protocol #: EX1250-4080 - A trial
comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type
2 diabetes at high risk of cardiovascular events
Main Clinical ResearchCoordinator: Novartis - A randomized double-blind, placebo
controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal
women with hormone receptor positive, HER2-negative, advanced breast cancer who received
no prior therapy for advanced disease
Main Clinical ResearchCoordinator: Pfizer Pharmaceuticals - A Phase 3 Randomized,
Double-Blind Study of PF-05280014 plus Paclitaxel versus Trastuzumab Plus Paclitaxel for the
first-line treatment of patients with HER2-Positive Metastatic Breast Cancer

5. Main Clinical ResearchCoordinator: Protocol #: M12-671: A Phase 3 Randomized, Double-
Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with
Moderate to Severe Endometriosis-Associated Pain